Moreover, in studies involving NUP98-NSD1+ AML, the use of EZH2 enzymatic inhibitors demonstrated that tumorigenicity was dependent on PRC2/EZH2 (Ren et al., 2022). Here, NSD1 is linked to acute myeloid leukemia.